These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14501983)

  • 41. [Expensive modern therapy options in intensive care medicine in Germany-- are they being used? Results of a questionnaire].
    Boldt J; Papsdorf M
    Dtsch Med Wochenschr; 2005 Jan; 130(3):87-91. PubMed ID: 15650957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 43. The story of drotrecogin alfa - evidence-based or evidence-biased?
    Wiseman R; Blockman M
    S Afr Med J; 2011 Dec; 102(1):8. PubMed ID: 22273122
    [No Abstract]   [Full Text] [Related]  

  • 44. Management of sepsis in the critically ill patient: key aspects.
    Vincent JL
    Expert Opin Pharmacother; 2006 Oct; 7(15):2037-45. PubMed ID: 17020431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of activated protein C in real-life clinical practice.
    Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
    Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-cost sepsis drug forces pharmacists to weigh patients' future.
    Thompson CA
    Am J Health Syst Pharm; 2002 Apr; 59(8):692, 697. PubMed ID: 11977851
    [No Abstract]   [Full Text] [Related]  

  • 47. The economics of sepsis.
    Chalupka AN; Talmor D
    Crit Care Clin; 2012 Jan; 28(1):57-76, vi. PubMed ID: 22123099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 49. Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party.
    Angus DC
    Crit Care; 2012 Feb; 16(1):107. PubMed ID: 22309988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controversies in the treatment of sepsis.
    Sandrock CE; Albertson TE
    Semin Respir Crit Care Med; 2010 Feb; 31(1):66-78. PubMed ID: 20101549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. After Xigris, researchers look to new targets to combat sepsis.
    Williams SC
    Nat Med; 2012 Jul; 18(7):1001. PubMed ID: 22772543
    [No Abstract]   [Full Text] [Related]  

  • 52. A case series of drotrecogin alfa (activated) in lung transplant recipients.
    Daniels TL; Dummer JS; Bernard GR; Milstone AP
    Transplantation; 2006 Jun; 81(12):1739-42. PubMed ID: 16794542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Calculation of costs per inpatient day in an intensive care unit].
    Alvear V S; Canteros J; Rodríguez P
    Rev Med Chil; 2010 May; 138(5):558-66. PubMed ID: 20668810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drotrecogin alfa (activated) in severe sepsis.
    Tsalis K
    Med Sci Monit; 2004 Oct; 10(10):LE19. PubMed ID: 15448603
    [No Abstract]   [Full Text] [Related]  

  • 55. Approach to economic analysis in critical care.
    Kyeremanteng K; Wan C; D'Egidio G; Neilipovitz D
    J Crit Care; 2016 Dec; 36():92-96. PubMed ID: 27546754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of drotrecogin alfa (activated) in clinical practice: a stitch in time.
    Doig G
    Crit Care Med; 2008 Jan; 36(1):332-3. PubMed ID: 18158441
    [No Abstract]   [Full Text] [Related]  

  • 60. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.
    Jamdar S; Siriwardena AK
    Crit Care; 2005 Aug; 9(4):321-2. PubMed ID: 16137370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.